Markers for gut wall integrity : a novel diagnostic and prognostic tool in adult trauma patients?
Completed
- Conditions
- multi-trauma patientenaccidental injuriestrauma1001794310022114
- Registration Number
- NL-OMON35184
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 600
Inclusion Criteria
Trauma patients (every patient for which the UMCG trauma team will be summoned)
18 years of age or older
Exclusion Criteria
Age < 18
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>serum I-FABP, L-FABP and urine Claudin 3</p><br>
- Secondary Outcome Measures
Name Time Method <p>among others: age, sex, mechanism of injury, Revised Trauma Score (combining<br /><br>glascow coma scale, blood pressure and heart rate) upon admission, Abbreviated<br /><br>Injury Score/Injury Severity Score (anatomical scoring system for injury<br /><br>severity), EMTRA score (combining age, glascow coma scale, base excess, and<br /><br>prothrombin time) upon admission, SIRS score (combining temperature, heart<br /><br>rate, neutrophils count, respiratory rate, with a SIRS score >1 denoting the<br /><br>presence of SIRS), cytokine levels of TNFa, IL6, IL10</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular markers correlate with gut wall integrity in trauma patients as studied in NL-OMON35184?
How do FABP levels compare to standard-of-care diagnostics in predicting outcomes for multi-trauma patients?
Which biomarkers are most effective for identifying trauma patients at risk of gut wall compromise in observational studies?
What adverse events are associated with gut integrity biomarker testing in invasive trauma research protocols?
Are there combination therapies or alternative biomarkers being explored alongside FABP for trauma prognosis in clinical research?